Prediction of early recurrence and response to adjuvant Sorafenib for hepatocellular carcinoma after resection

BACKGROUND: Early recurrence of hepatocellular carcinoma (HCC) is a major obstacle to improving the prognosis, and no widely accepted adjuvant therapy guideline for patients post-liver resection is available. Currently, all available methods and biomarkers are insufficient to accurately predict post...

Descripción completa

Detalles Bibliográficos
Autores principales: Zheng, Liming, Gu, Xi, Zheng, Guojun, Li, Xin, He, Meifang, Liu, Longgen, Zhou, Xike
Formato: Online Artículo Texto
Lenguaje:English
Publicado: PeerJ Inc. 2021
Materias:
Bioinformatics
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8628622/
https://www.ncbi.nlm.nih.gov/pubmed/34900444
http://dx.doi.org/10.7717/peerj.12554

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8628622/
https://www.ncbi.nlm.nih.gov/pubmed/34900444
http://dx.doi.org/10.7717/peerj.12554

Ejemplares similares